Chapter 19: Antianxiety Medications

The content explores how benzodiazepines work by enhancing inhibitory gamma-aminobutyric acid activity at the neuronal level, thereby reducing excessive neural firing and promoting calming effects throughout the central nervous system. The chapter differentiates between short-acting and long-acting benzodiazepines, explaining how variations in drug half-life directly influence the development of physiological dependence, withdrawal severity, and clinical discontinuation protocols. Beyond benzodiazepines, the material covers alternative anxiolytic agents including beta-blockers that address somatic and autonomic manifestations of anxiety, antihistamines used in clinical practice, and buspirone as a non-benzodiazepine anxiolytic option. The chapter then transitions to antipsychotic medications, contrasting first-generation typical antipsychotics with newer second-generation atypical antipsychotics in terms of efficacy, safety profiles, and receptor selectivity. A central theoretical framework discussed is the dopamine hypothesis of schizophrenia, which proposes that antipsychotic efficacy results from dopamine antagonism in specific brain regions, thereby reducing psychotic symptoms. The material addresses critical adverse effects associated with antipsychotic use, particularly extrapyramidal side effects that include akathisia and dystonia, as well as tardive dyskinesia, a potentially irreversible movement disorder emerging from chronic dopamine blockade. The chapter also covers clinical applications of antipsychotics beyond schizophrenia, including their use in bipolar disorder management and acute agitation, while emphasizing the importance of risk-benefit assessment in prescribing decisions and ongoing patient monitoring.